<DOC>
	<DOCNO>NCT00857558</DOCNO>
	<brief_summary>A multicenter , randomize , double-blind , placebo-controlled , group-comparison study investigate safety efficacy OPC-262 patient type 2 diabetes</brief_summary>
	<brief_title>A Phase 2 Study OPC-262 Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<criteria>Type 2 diabetes patient HbA1c 7.0 % 10 % Patients capable give informed consent Patients able take contraceptive measure avoid pregnancy patient patient 's partner Patients type1 diabetes mellitus , patient diabetes mellitus impair glucose tolerance ( IGT ) due specify mechanism disease , patient gestational diabetes mellitus Patients medical history diabetes coma Patients poorlycontrolled hypertension Patients heart failure Patients complication active hepatitis hepatic cirrhosis Patients undergoing treatment glomeruler diseases diabetic nephropathy Patients history complication malignant tumor</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>